143 related articles for article (PubMed ID: 8988011)
1. Determination of affinities for lck SH2 binding peptides using a sensitive fluorescence assay: comparison between the pYEEIP and pYQPQP consensus sequences reveals context-dependent binding specificity.
Cousins-Wasti RC; Ingraham RH; Morelock MM; Grygon CA
Biochemistry; 1996 Dec; 35(51):16746-52. PubMed ID: 8988011
[TBL] [Abstract][Full Text] [Related]
2. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck.
Eck MJ; Shoelson SE; Harrison SC
Nature; 1993 Mar; 362(6415):87-91. PubMed ID: 7680435
[TBL] [Abstract][Full Text] [Related]
3. Mutational investigation of the specificity determining region of the Src SH2 domain.
Bradshaw JM; Mitaxov V; Waksman G
J Mol Biol; 2000 Jun; 299(2):521-35. PubMed ID: 10860756
[TBL] [Abstract][Full Text] [Related]
4. Alternative mode of binding to phosphotyrosyl peptides by Src homology-2 domains.
Qin C; Wavreille AS; Pei D
Biochemistry; 2005 Sep; 44(36):12196-202. PubMed ID: 16142918
[TBL] [Abstract][Full Text] [Related]
5. Solid-phase binding assays of peptides using EGFP-Src SH2 domain fusion protein and biotinylated Src SH2 domain.
Ye G; Ayrapetov M; Nam NH; Sun G; Parang K
Bioorg Med Chem Lett; 2005 Nov; 15(22):4994-7. PubMed ID: 16169725
[TBL] [Abstract][Full Text] [Related]
6. Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution.
Tong L; Warren TC; King J; Betageri R; Rose J; Jakes S
J Mol Biol; 1996 Mar; 256(3):601-10. PubMed ID: 8604142
[TBL] [Abstract][Full Text] [Related]
7. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
[TBL] [Abstract][Full Text] [Related]
8. Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase.
Bradshaw JM; Mitaxov V; Waksman G
J Mol Biol; 1999 Nov; 293(4):971-85. PubMed ID: 10543978
[TBL] [Abstract][Full Text] [Related]
9. The three-dimensional solution structure of the SH2 domain from p55blk kinase.
Metzler WJ; Leiting B; Pryor K; Mueller L; Farmer BT
Biochemistry; 1996 May; 35(20):6201-11. PubMed ID: 8639560
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of rosmarinic acid on Lck SH2 domain binding to a synthetic phosphopeptide.
Ahn SC; Oh WK; Kim BY; Kang DO; Kim MS; Heo GY; Ahn JS
Planta Med; 2003 Jul; 69(7):642-6. PubMed ID: 12898421
[TBL] [Abstract][Full Text] [Related]
11. Solution structure of the C-terminal SH2 domain of the p85 alpha regulatory subunit of phosphoinositide 3-kinase.
Siegal G; Davis B; Kristensen SM; Sankar A; Linacre J; Stein RC; Panayotou G; Waterfield MD; Driscoll PC
J Mol Biol; 1998 Feb; 276(2):461-78. PubMed ID: 9512716
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of the SH2 domain of Grb2: highlight on the binding of a new high-affinity inhibitor.
Nioche P; Liu WQ; Broutin I; Charbonnier F; Latreille MT; Vidal M; Roques B; Garbay C; Ducruix A
J Mol Biol; 2002 Feb; 315(5):1167-77. PubMed ID: 11827484
[TBL] [Abstract][Full Text] [Related]
13. Phosphopeptide ligands of the SHP-1 N-SH2 domain: effects on binding and stimulation of phosphatase activity.
Hampel K; Kaufhold I; Zacharias M; Böhmer FD; Imhof D
ChemMedChem; 2006 Aug; 1(8):869-77. PubMed ID: 16902940
[TBL] [Abstract][Full Text] [Related]
14. Phosphotyrosine-containing dipeptides as high-affinity ligands for the p56lck SH2 domain.
Llinaś-Brunet M; Beaulieu PL; Cameron DR; Ferland JM; Gauthier J; Ghiro E; Gillard J; Gorys V; Poirier M; Rancourt J; Wernic D; Betageri R; Cardozo M; Jakes S; Lukas S; Patel U; Proudfoot J; Moss N
J Med Chem; 1999 Feb; 42(4):722-9. PubMed ID: 10052978
[TBL] [Abstract][Full Text] [Related]
15. Dissection of the energetic coupling across the Src SH2 domain-tyrosyl phosphopeptide interface.
Lubman OY; Waksman G
J Mol Biol; 2002 Feb; 316(2):291-304. PubMed ID: 11851339
[TBL] [Abstract][Full Text] [Related]
16. Insights into human Lck SH3 domain binding specificity: different binding modes of artificial and native ligands.
Tran T; Hoffmann S; Wiesehan K; Jonas E; Luge C; Aladag A; Willbold D
Biochemistry; 2005 Nov; 44(45):15042-52. PubMed ID: 16274251
[TBL] [Abstract][Full Text] [Related]
17. Binding, domain orientation, and dynamics of the Lck SH3-SH2 domain pair and comparison with other Src-family kinases.
Hofmann G; Schweimer K; Kiessling A; Hofinger E; Bauer F; Hoffmann S; Rösch P; Campbell ID; Werner JM; Sticht H
Biochemistry; 2005 Oct; 44(39):13043-50. PubMed ID: 16185072
[TBL] [Abstract][Full Text] [Related]
18. Design and biological evaluation of linear and cyclic phosphopeptide ligands of the N-terminal SH2 domain of protein tyrosine phosphatase SHP-1.
Imhof D; Wieligmann K; Hampel K; Nothmann D; Zoda MS; Schmidt-Arras D; Zacharias M; Böhmer FD; Reissmann S
J Med Chem; 2005 Mar; 48(5):1528-39. PubMed ID: 15743195
[TBL] [Abstract][Full Text] [Related]
19. The specificity of the N-terminal SH2 domain of SHP-2 is modified by a single point mutation.
Huyer G; Ramachandran C
Biochemistry; 1998 Mar; 37(9):2741-7. PubMed ID: 9485424
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure analysis and solution studies of human Lck-SH3; zinc-induced homodimerization competes with the binding of proline-rich motifs.
Romir J; Lilie H; Egerer-Sieber C; Bauer F; Sticht H; Muller YA
J Mol Biol; 2007 Feb; 365(5):1417-28. PubMed ID: 17118402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
